Accéder au contenu
Merck
Toutes les photos(1)

Documents

L9787

Sigma-Aldrich

L-655,708

≥98% (HPLC), powder

Synonyme(s) :

Ethyl (S)-11,12,13,13a-Tetrahydro-7-methoxy-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylate, L-655708

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H19N3O4
Numéro CAS:
130477-52-0
Poids moléculaire :
341.36
Numéro MDL:
MFCD02684528
Code UNSPSC :
12352200
ID de substance PubChem :
24278527
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Solubilité

DMSO: ≥6.0 mg/mL (Warmed)
H2O: insoluble

Auteur

Merck & Co., Inc., Kenilworth, NJ, U.S.

Chaîne SMILES 

CCOC(=O)c1ncn2-c3ccc(OC)cc3C(=O)N4CCCC4c12

InChI

1S/C18H19N3O4/c1-3-25-18(23)15-16-14-5-4-8-20(14)17(22)12-9-11(24-2)6-7-13(12)21(16)10-19-15/h6-7,9-10,14H,3-5,8H2,1-2H3/t14-/m0/s1

Clé InChI

YKYOQIXTECBVBB-AWEZNQCLSA-N

Informations sur le gène

human ... GABRA5(2558)

Application

L-655,708 has been used as an α5 GABAA receptor inverse agonist to inhibit the discriminative stimulus of propofol in a dose-dependent manner.

Actions biochimiques/physiologiques

L-655,708 is an inverse agonist of the α5 γ-Aminobutyric acid type A (GABAA) receptor. It has an ability to increase cognition in rats.
Novel ligand selective for the benzodiazepine site of GABAA receptors which contain the α5 subunit.

Caractéristiques et avantages

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Flavia R Carreno et al.
The international journal of neuropsychopharmacology, 20(6), 504-509 (2017-03-25)
Selective augmentation of hippocampal activity in ways similar to that caused by ketamine may have therapeutic advantages over ketamine, which has psychotomimetic and reinforcing effects likely due to effects outside the hippocampus (i.e., off-target effects). Here we evaluated the antidepressant-like
C Sur et al.
Molecular pharmacology, 54(5), 928-933 (1998-11-06)
The gamma-aminobutyric acid (GABA)A receptor is a hetero-oligomer consisting of five subunits, the combination of which confers unique pharmacological properties to the receptor. To understand the physiological role of native GABAA receptors, it is critical to determine their subunit compositions.
L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors
Atack JR, et al.
Neuropharmacology, 51(6), 1023-1029 (2006)
M Xue et al.
European journal of pain (London, England), 21(6), 1061-1071 (2017-02-02)
γ-Aminobutyric acid (GABA) type A receptors (GABA The C fibre-evoked field potentials were recorded in superficial dorsal horn of spinal cord, and the effects of α5-GABA Inhibition of α5-GABA α5-GABA Tonic inhibition generated by α5-GABA
Jonathan Fischell et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(11), 2499-2509 (2015-04-23)
Selective serotonin reuptake inhibitors (SSRIs) are the primary pharmacological treatment for depression, but SSRIs are effective in only half of the patients and typically take several weeks to relieve symptoms. The NMDA receptor antagonist ketamine exerts a rapid antidepressant action
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique